CA2021500A1 - Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique - Google Patents

Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique

Info

Publication number
CA2021500A1
CA2021500A1 CA2021500A CA2021500A CA2021500A1 CA 2021500 A1 CA2021500 A1 CA 2021500A1 CA 2021500 A CA2021500 A CA 2021500A CA 2021500 A CA2021500 A CA 2021500A CA 2021500 A1 CA2021500 A1 CA 2021500A1
Authority
CA
Canada
Prior art keywords
peripheral blood
blood lymphocytes
stimulating proliferation
subpopulations
starting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2021500A
Other languages
English (en)
Other versions
CA2021500C (fr
Inventor
Teruaki Sekine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23515405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2021500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of CA2021500A1 publication Critical patent/CA2021500A1/fr
Application granted granted Critical
Publication of CA2021500C publication Critical patent/CA2021500C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002021500A 1989-07-21 1990-07-19 Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique Expired - Lifetime CA2021500C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38394289A 1989-07-21 1989-07-21
US383,942 1989-07-21

Publications (2)

Publication Number Publication Date
CA2021500A1 true CA2021500A1 (fr) 1991-01-22
CA2021500C CA2021500C (fr) 1995-06-13

Family

ID=23515405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002021500A Expired - Lifetime CA2021500C (fr) 1989-07-21 1990-07-19 Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique

Country Status (7)

Country Link
EP (1) EP0409655A3 (fr)
JP (1) JP3056230B2 (fr)
AU (1) AU633940B2 (fr)
CA (1) CA2021500C (fr)
GR (1) GR1001034B (fr)
IE (1) IE902662A1 (fr)
ZA (1) ZA905735B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
AU663711B2 (en) * 1991-04-05 1995-10-19 Regents Of The University Of Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
WO1995032729A1 (fr) * 1994-05-31 1995-12-07 Augusto Carlos Ochoa Stimulation anti-cd3 a court terme des lymphocytes destinee a en accroitre l'activite in vivo
EP0910624B1 (fr) * 1996-04-17 2004-09-22 Albert, Winfried, Dr. Procede de production et de multiplication de lymphocytes
US6511848B2 (en) 1996-04-17 2003-01-28 Winfried Albert Process for producing and multiplying lymphocytes
JP4186013B2 (ja) * 1996-07-15 2008-11-26 暉彬 関根 ウイルス感染症の治療・予防剤、その調製方法
SE511143C2 (sv) 1997-12-30 1999-08-09 Sca Hygiene Paper Ab Metod att framställa ett papper uppvisande en tredimensionellt mönster
JP2001354575A (ja) 2000-06-09 2001-12-25 Human Tekku:Kk 癌の再発予防法および癌の再発予防用活性化リンパ球を含む製剤、ならびにそれらの細胞の凍結および加工委・受託システム
JP4917201B2 (ja) * 2000-12-04 2012-04-18 株式会社リンフォテック 臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
WO2002069990A1 (fr) * 2001-03-05 2002-09-12 Lymphotec Inc. Methode de traitement d'une tumeur et systeme servant a la proliferation et au traitement de lymphocytes activees destinees a une utilisation parallele a la therapie tpd
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
CN100591760C (zh) 2002-03-25 2010-02-24 宝生物工程株式会社 制备细胞毒性淋巴细胞的方法
JP4562353B2 (ja) * 2002-04-08 2010-10-13 株式会社リンフォテック Ｈｌａ一致他人由来活性化リンパ球を含有してなる腫瘍・感染症および自己免疫疾患の予防・治療用製剤
US20070025961A1 (en) 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
US8927273B2 (en) 2003-08-22 2015-01-06 Takara Bio Inc. Process for producing cytotoxic lymphocytes
JP2006143709A (ja) * 2004-10-20 2006-06-08 Lymphotec:Kk 薬剤耐性原生生物感染症の治療もしくは予防用製剤、該製剤の調製用キットおよび調製方法、薬剤耐性原生生物感染症の治療方法
KR101279172B1 (ko) * 2005-08-17 2013-06-27 다카라 바이오 가부시키가이샤 림프구의 제조 방법
EP2390363A1 (fr) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals s.a. Procédé d'identification si un patient est réactif ou non à l'immunothérapie basé sur l'expression différentielle du gène PRF1
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
JP7158682B2 (ja) * 2016-12-27 2022-10-24 住友化学株式会社 染色体の異常の検出方法および誘発性を評価する方法
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2021085504A1 (fr) 2019-11-01 2021-05-06 京都府公立大学法人 Récepteur d'anticorps de lympocyte b et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2529321B2 (ja) * 1986-04-28 1996-08-28 エンドトロニックス インコーポレーテッド 白血球を培養する方法
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
DE3634017A1 (de) * 1986-10-06 1988-04-14 Max Planck Gesellschaft Verfahren zur aktivierung und vermehrung von t-zellen, insbesondere von deren subpopulationen
AU4485089A (en) * 1988-10-21 1990-05-14 Brigham And Women's Hospital Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr

Also Published As

Publication number Publication date
CA2021500C (fr) 1995-06-13
JP3056230B2 (ja) 2000-06-26
IE902662A1 (en) 1991-02-27
GR900100551A (fr) 1991-12-10
ZA905735B (en) 1992-03-25
GR1001034B (el) 1993-03-31
EP0409655A2 (fr) 1991-01-23
AU633940B2 (en) 1993-02-11
EP0409655A3 (en) 1992-04-15
JPH0380076A (ja) 1991-04-04
AU5918290A (en) 1991-01-24

Similar Documents

Publication Publication Date Title
CA2021500A1 (fr) Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique
HUT64595A (en) Method for producing mammalian cytokine, il-11
AU1551888A (en) Intercellular adhesion molecules and their binding ligands
KR890003381B1 (en) Forming method of thin n-type area
MX9703681A (es) Metodo para hacer una coleccion de compuestos.
GR3023723T3 (en) Method of activating cytolytic activity of lymphocytes using anti-CD28 antibody
EP2298804A3 (fr) Production d'anticorps monoclonaux par transformation par EBV de lymphocytes B
AU1868695A (en) Immuno-stimulatory monoclonal antibodies
DK0716685T3 (da) Granulat indeholdende flere enzymer
EP0365837A3 (fr) Molécules d'adhésion intercellulaire et leurs ligands de liaison
MX9605088A (es) Metodos para proliferar y diferenciar celulas b y sus usos.
EP0628628A4 (fr) Bacterie gla ogene, culture de ladite bacterie, substance gla ogene contenant ladite bacterie et utilisation de ladite substance.
DE3476221D1 (en) Method for obtaining human hepatocytes cultures, cultures obtained thereby and biological and biochemical applications thereof
MY106561A (en) Method of making factor-dependent human b cell lines
EP0291728A3 (fr) Production d'interféron immun et son ARN-m
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
Mosca et al. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand
AU8225582A (en) Prepared nutrient substrate carrier for the qualitative and quantitative determination of microorganisms
BG102513A (en) Method for the diagnostics and the treatment of flat cellular cancer
AU2390984A (en) Cell culture apparatus and process using an immobilized cell composite
EP0160486A3 (en) Monoclonal antibodies
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
ES8501530A1 (es) Metodo de ensayo de anticuerpos.
DE69012105D1 (en) Proliferation von cd4-lymfocyten.
ATE48442T1 (de) Erwachsene-t-zellen-leukaemie verbundene zellinien, verfahren zur herstellung dieser linie und gegenserum.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202